[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hbv-related-liver-cirrhosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hbv-related-liver-cirrhosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100614127","analysis-of-methylomic-features-and-prognostic-risk-prediction-in-patients-with-hepatitis-b-related-acute-on-chronic-liver-failure-100614127",false,"NCT07275554","Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure","Inclusion Criteria:\n\n* Chronic hepatitis B was persistent hepatitis B surface antigen (HBsAg) seropositivity for more than six months.\n\nHepatitis B-related liver cirrhosis was diagnosed based on histological examination, typical features on ultrasound or radiological imaging, endoscopic findings of portal hypertension, and clinical history.\n\nHepatitis B-related acute-on-chronic liver failure meets the diagnostic criteria of the 2018 Asia-Pacific guidelines for the diagnosis and treatment of liver failure.Laboratory tests:Jaundice: Serum total bilirubin ≥ 85 µmol\u002FL and coagulopathy \\[International Normalized Ratio (INR) ≥ 1.5 or Prothrombin Activity (PTA) \\\u003C 40%\\].\n\nExclusion Criteria:\n\n* co-infection with other hepatitis viruses; history of hepatocellular carcinoma or other malignancies; concomitant autoimmune liver disease; or insufficient clinical data.","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model. The findings are of significant importance for guiding clinical practice and improving patient prognosis. Additionally, a methylomics-based classifier model for liver failure will be developed for disease prognosis analysis and clinical assessment, with the potential to enhance the diagnostic efficiency of liver failure.",[23,24,25],"HBV Related Acute-on-chronic Liver Failure","HBV-related Liver Cirrhosis","HBV (Hepatitis B Virus)","RECRUITING","2025-11-27",{"date":29,"type":30},"2025-12-10","ACTUAL",{"date":32,"type":30},"2024-12-31",{"date":34,"type":19},"2026-12-31",{"name":36,"class":37},"Qilu Hospital of Shandong University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100607033","a-study-on-peginterferon-alfa-2b-combined-with-nas-in-compensated-hbv-cirrhosis-100607033","NCT07183293","A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis","A Multicenter, Randomized, Prospective Study on the Efficacy and Safety of Peginterferon Alfa-2b Combined With Nucleos(t)Ide Analogues in Patients With Compensated HBV-Related Liver Cirrhosis","Inclusion Criteria:\n\n1. Clinical diagnosis of compensated HBV-related liver cirrhosis (Child-Pugh class A or B);\n2. The subject is able to understand and comply with the content, requirements, and restrictions of the protocol, is willing and able to complete the study per protocol requirements, fully understands the potential adverse reactions, and voluntarily provides written informed consent prior to study initiation;\n3. Aged 18 to 60 years (inclusive), any gender;\n4. Female subjects of childbearing potential must have a negative pregnancy test at screening;\n5. Subjects (including their partners) must voluntarily use effective non-drug contraception from prior to dosing until six months after discontinuation of the study drug and have no plan to donate sperm or ova; or subjects (including their partners) are of non-childbearing potential (surgically sterilized or postmenopausal).\n\nExclusion Criteria:\n\n1. Decompensated liver cirrhosis, hepatic failure, or hepatocellular carcinoma; presence of other liver diseases such as fatty liver disease, alcoholic liver disease, drug-induced liver injury, autoimmune liver disease, or Wilson's disease;\n2. History of clinically significant diseases of the cardiovascular, hematological and lymphatic, respiratory, urinary, endocrine, immune, psychiatric, or nervous systems (e.g., epilepsy), ophthalmic diseases, or thyroid-related disorders;\n3. Pregnancy, lactation, or intention to become pregnant during the study period;\n4. Known or suspected allergy to the investigational product(s) or any of its excipients;\n5. Participation in any other interventional clinical trial within 3 months prior to screening or planning to participate in another clinical trial during the study;\n6. Any other condition considered by the investigator to be inappropriate for participation in the study.","60 Years",{"count":48,"type":19},30,"INTERVENTIONAL",[51],"NA","This study is a multicenter, randomized, prospective trial designed to evaluate the efficacy and safety of pegylated interferon α-2b (Peg-IFN-α2b) combined with nucleos(t)ide analogues (NAs) versus NAs monotherapy in patients with compensated hepatitis B cirrhosis. A total of 30 patients with compensated HBV-related cirrhosis will be enrolled and randomized in a 2:1 ratio to either Experimental Group 1 (n=20) or Experimental Group 2 (n=10). The treatment regimens consist of Peg-IFN-α2b combined with NAs (ETV\u002FTAF\u002FTMF\u002FTDF) or NAs (ETV\u002FTAF\u002FTMF\u002FTDF) monotherapy.",[24],[55],"Peginterferon α-2b","NOT_YET_RECRUITING","2025-09-17",{"date":59,"type":30},"2025-09-19",{"date":61,"type":19},"2025-10",{"date":63,"type":19},"2031-09",{"name":65,"class":37},"Xiamen Humanity Hospital",2,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":78,"studyType":20,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":38},"100605317","risk-assessment-for-hbv-related-liver-cancer-100605317","NCT07160946","Risk Assessment for HBV-Related Liver Cancer","Research on Risk Assessment and Intervention of HBV-Related Liver Cancer Based on Multimodal Data Fusion","Inclusion Criteria: must meet (a) and any one of (b) to (g).\n\n* (a).Positive for Hepatitis B surface antigen; (b).Ultrasound\u002FCT\u002FMR indicates liver cirrhosis; (c). Type II diabetes; (d). Has family history of liver cirrhosis\u002F liver cancer; (e). Long term alcohol consumption history (\\>5 years), equivalent to alcohol consumption of ≥ 40g\u002Fd for males and ≥ 20g\u002Fd for females; (f). Liver histology Metavir fibrosis score F3 or above; (g). Fibroscan value (LSM) ≥ 8.0kPa.\n\nExclusion Criteria:\n\n* (a).Diagnosed with malignant tumors; (b). Post liver transplantation; (c). Infected with HIV; (d). Expected survival time\\\u003C1 year; (e). With marked organ dysfunctions(heart, brain, kidney, lung, endocrine system, blood, etc.) or psychiatric patients.","30 Years","75 Years",{"count":77,"type":19},6000,"5 Years","Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.",[24],"2025-08-31",{"date":83,"type":30},"2025-09-08",{"date":85,"type":30},"2025-05-10",{"date":87,"type":19},"2032-12-30",{"name":89,"class":37},"Sun Yat-sen University"]